Our data demonstrated that initiation of empagliflozin treatment substantially reduced estimated fluid volume parameters in patients with type 2 diabetes and CVD, and that this effect was maintained for 24 weeks. Given the early beneficial effect of empagliflozin on cardiovascular outcomes seen in similar patient populations, our findings provide an important insight into the key mechanisms underlying the clinical benefit of the drug (Cardiovascular Diabetology)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
